Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?
- PMID: 29880290
- DOI: 10.1016/S1470-2045(18)30409-1
Abiraterone plus olaparib in prostate cancer: a new form of synthetic lethality?
Comment on
-
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.Lancet Oncol. 2018 Jul;19(7):975-986. doi: 10.1016/S1470-2045(18)30365-6. Epub 2018 Jun 4. Lancet Oncol. 2018. PMID: 29880291 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
